Dexcom Executive Chair Kevin Sayer Sells Over 26,700 Shares Under Prearranged Trading Plan

Executive Leadership Equity Transaction Details

Kevin R. Sayer, who holds the position of Executive Chair and serves as a director of Dexcom Inc., executed a share sale transaction on July 20, 2026. The transaction involved the disposition of 26,756 shares of Dexcom common stock, representing an orderly reduction in his shareholdings. According to the regulatory disclosure, the shares were sold through multiple individual trades rather than a single transaction, with prices ranging from $75.80 to $76.62 per share during the execution period.

The weighted average sale price across all trades executed on that date was $76.3193 per share. Following this disposition, Sayer's direct beneficial ownership position in Dexcom comprised 328,970 shares. This remaining stake includes both fully vested shares and a significant number of unvested restricted stock units that represent future equity compensation components of his executive compensation arrangement.

Rule 10b5-1 Trading Plan Framework and Adoption Timeline

The share sale was executed pursuant to a Rule 10b5-1 trading plan that Sayer adopted on February 18, 2026. These prearranged trading plans allow company insiders to establish predetermined arrangements for the sale of securities in a manner designed to satisfy affirmative defense conditions under securities regulations. By adopting such a plan, Sayer established a framework for the orderly disposition of his shareholdings over time, removing discretionary trading decisions from specific market conditions.

The Rule 10b5-1 mechanism provides a structured approach that can help insiders manage their investment portfolios while maintaining compliance with insider trading restrictions. The plan adopted by Sayer in February 2026 governed the July 20, 2026 transaction and may authorize future share sales under the prearranged terms established at the time of adoption. This trading framework demonstrates a transparent approach to executive equity management at the company.

Restricted Stock Unit Composition and Vesting Schedule

Among the 328,970 shares in Sayer's direct beneficial ownership following the transaction, 106,972 shares represent unvested restricted stock units with varying grant dates and vesting periods. These restricted units constitute a significant portion of his equity stake and reflect the company's use of equity-based compensation to align executive interests with shareholder returns. The vesting schedule for these units extends across multiple calendar years, indicating staggered compensation delivery.

The restricted stock units break down into three separate cohorts based on grant timing. A grant of 32,749 units issued on March 8, 2026, is scheduled to vest through March 8, 2027, representing the most recent equity grant. An earlier grant of 56,993 units from March 8, 2025, will vest through March 8, 2028, representing a two-year vesting period. Additionally, 17,230 units granted on March 8, 2024, are scheduled to vest through March 8, 2027. This multi-year vesting structure ensures continued alignment between executive compensation and long-term company performance.

Dexcom's Business Model and Market Position

Dexcom Inc. operates as a medical technology company focused on continuous glucose monitoring systems, serving patients with diabetes across multiple market segments globally. The company develops and commercializes wearable glucose monitoring devices and associated software platforms that enable real-time glucose trend information and alerts. This market operates within the broader diabetes management and digital health technology sectors, which have experienced significant growth driven by increasing prevalence of diabetes and demand for remote patient monitoring solutions.

The company's revenue model centers on sales of continuous glucose monitoring systems, including the hardware devices that patients wear as well as recurring revenue from sensor replacements and platform subscriptions. Dexcom serves healthcare providers, payers, and patients directly, with international expansion representing a significant growth opportunity. The company's positioned within the broader digital health and medical device industries, where regulatory approvals, reimbursement policies, and technological innovation drive competitive dynamics and revenue growth trajectories.

Insider Ownership Position and Executive Compensation Structure

Sayer's beneficial ownership position of 328,970 shares represents his stake in company equity following the July 2026 transaction. His role as Executive Chair and director places him among the company's senior leadership, with responsibilities for strategic direction and corporate governance. The composition of his ownership, including substantial unvested restricted stock units, reflects typical executive compensation arrangements that combine cash compensation with long-term equity incentives designed to retain talent and motivate performance.

The vesting schedule for Sayer's restricted units indicates ongoing equity compensation arrangements that will deliver shares over the coming months and years contingent on his continued service. This structure is common in public company executive compensation, where equity grants vest over multi-year periods to encourage long-term commitment. The presence of multiple vesting cohorts suggests that Sayer has received periodic equity grants as part of annual compensation reviews or other corporate actions.

Transaction Execution and Price Range Documentation

The July 20, 2026 sale was executed through multiple individual trades rather than a single transaction, with the disclosure document indicating that individual trade prices ranged from $75.80 to $76.62 per share. The weighted average price of $76.3193 reflects the blended result across all shares sold during the trading day. This execution approach is typical for larger share dispositions, where orders may be executed in tranches to manage market impact and achieve favorable execution pricing.

The reporting documentation commits Sayer to provide full information regarding the specific number of shares sold at each price point upon request to the Securities and Exchange Commission staff, the company, or company shareholders. This transparency requirement ensures that detailed transaction records are available for regulatory review and investor scrutiny, demonstrating compliance with disclosure obligations. The price range and execution methodology were typical for equity transactions of this size and nature during normal trading conditions.

Regulatory Compliance and Insider Trading Framework

The transaction was reported through an insider trading disclosure document filed on July 21, 2026, the day following the share sale. As a director and executive officer of a publicly traded company, Sayer is subject to Section 16 reporting requirements that mandate disclosure of beneficial ownership changes within two trading days of transaction completion. The filing indicates that Sayer selected the checkbox confirming that the transaction was executed pursuant to a Rule 10b5-1 trading plan, establishing the lawful framework for the equity disposition.

The regulatory framework governing insider transactions serves to inform investors and regulators about significant changes in officer and director shareholdings while also protecting insiders from liability for trades executed under prearranged plans established during non-trading window periods. By utilizing the Rule 10b5-1 mechanism, Sayer demonstrates adherence to established securities law procedures designed to balance insider liquidity needs with investor protection objectives. The timely filing of the transaction report maintains transparency regarding changes in company leadership shareholdings.

Director and Officer Status Within Company Governance Structure

Kevin R. Sayer holds dual roles within Dexcom's corporate structure, serving simultaneously as Executive Chair and as a member of the board of directors. These positions place him among the company's highest-ranking executives with responsibilities spanning both day-to-day strategic operations and board-level governance oversight. His continued significant shareholding, including the 328,970 shares retained following the July transaction, indicates substantial personal financial investment in company success and shareholder value creation.

The combination of executive and director roles reflects a governance structure where senior leadership maintains close alignment with shareholder interests through material equity ownership. The vesting schedule of Sayer's restricted stock units extending through 2028 suggests expected continuation in these leadership positions for at least the coming two years. His shareholding position and equity compensation arrangements create direct financial incentives for strategic decision-making that prioritizes long-term shareholder value.

Market Context and Equity Compensation Trends in Medical Device Industry

The medical device and digital health technology sectors have characterized executive compensation strategies increasingly around equity-based awards, particularly restricted stock units that vest over multi-year periods. This compensation approach has become standard practice across the industry to attract and retain executive talent while aligning leadership compensation with shareholder returns. Dexcom's use of restricted stock units with March vesting dates and multi-year vesting periods reflects industry-standard practices in executive retention and incentive alignment.

The July 2026 transaction represents one element of Sayer's ongoing equity management, conducted within a prearranged trading framework established during the prior fiscal period. Share sales by executives and directors in publicly traded medical device and health technology companies are routine occurrences, often reflecting portfolio rebalancing, diversification objectives, or personal liquidity needs rather than commentary on company prospects. The continuation of Sayer's substantial shareholding position, even following the disposition, suggests confidence in company long-term value creation.